98%
921
2 minutes
20
Purpose: The molecular mechanisms involved in bone metabolism abnormalities in individuals with type 2 diabetes mellitus (T2DM) are a prominent area of investigation within the life sciences field. Myostatin (MSTN), a member of the TGF-β superfamily, serves as a critical negative regulator of skeletal muscle growth and bone metabolism. Current research on the exercise-mediated regulation of MSTN expression predominantly focuses on its role in skeletal muscle. However, due to the intricate and multifaceted mechanical and biochemical interactions between muscle and bone, the precise mechanisms by which exercise modulates MSTN to enhance bone metabolic disorders in T2DM necessitate additional exploration. The objective of this review is to systematically synthesize and evaluate the role of MSTN in the development of bone metabolism disorders associated with T2DM and elucidate the underlying mechanisms influenced by exercise interventions, aiming to offer novel insights and theoretical recommendations for enhancing bone health through physical activity.
Methods: Relevant articles in Chinese and English up to July 2024 were selected using specific search terms and databases (PubMed, CNKI, Web of Science); 147 studies were finally included after evaluation, and the reference lists were checked for other relevant research.
Results: Myostatin's heightened expression in the bone and skeletal muscle of individuals with T2DM can impede various pathways, such as PI3K/AKT/mTOR and Wnt/β-catenin, hindering osteoblast differentiation and bone mineralization. Additionally, it can stimulate osteoclast differentiation and bone resorption capacity by facilitating Smad2-dependent NFATc1 nuclear translocation and PI3K/AKT/AP-1-mediated pro-inflammatory factor expression pathways, thereby contributing to bone metabolism disorders. Physical exercise plays a crucial role in ameliorating bone metabolism abnormalities in individuals with T2DM. Exercise can activate pathways like Wnt/GSK-3β/β-catenin, thereby suppressing myostatin and downstream Smads, CCL20/CCR6, and Nox4 target gene expression, fostering bone formation, inhibiting bone resorption, and enhancing bone metabolism in T2DM.
Conclusion: In the context of T2DM, MSTN has been shown to exacerbate bone metabolic disorders by inhibiting the differentiation of osteoblasts and the process of bone mineralization while simultaneously promoting the differentiation and activity of osteoclasts. Exercise interventions have demonstrated efficacy in downregulating MSTN expression, disrupting its downstream signaling pathways, and enhancing bone metabolism.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941426 | PMC |
http://dx.doi.org/10.3390/cimb47030158 | DOI Listing |
Tissue Eng Regen Med
September 2025
Department of Joint and Sports Medicine, Chaoyang Central Hospital, Chaoyang City, Liaoning Province, China.
Background: Osteoarthritis (OA) represents a major global health challenge with no ideal treatment options available. Early-stage treatment typically focuses on symptomatic relief of pain and stiffness; while late-stage patients can only opt for surgical interventions such as joint replacement to improve quality of life. Cell-free therapy based on extracellular vesicles (EVs) has offered a novel therapeutic approach for regulating bone metabolism and repairing cartilage, demonstrating emerging potential.
View Article and Find Full Text PDFAdv Mater
September 2025
State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China.
Bone defect therapy frequently encounters bacterial infections and chronic inflammation, which impair bone regeneration and threaten implant stability. Iron oxide nanoparticles have attracted attention due to cost-effectiveness, biocompatibility, and metabolic safety. However, iron oxide nanoparticles still struggle to balance low-temperature efficient antibacterial activity, effective immunomodulation, and bone regeneration.
View Article and Find Full Text PDFEur J Case Rep Intern Med
August 2025
General medicine department, Universidad de Cartagena, Cartagena, Colombia.
Background: Romosozumab is a sclerostin-inhibiting monoclonal antibody that is effective and safe for anabolic treatment in patients with osteoporosis. Its main adverse effects are local; the severity of these injection-site reactions in clinical trials was generally mild.
Case Report: We present a case of a 71-year-old Colombian woman with osteoporosis at very high risk of fractures with no relevant history of drug allergies.
Front Endocrinol (Lausanne)
September 2025
Department of Orthopedics I, Second Affiliated Hospital, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, China.
Background: Emerging evidence indicates that lactase-mediated histone lactylation can activate osteogenic gene expression and promote bone formation. However, the role of lactylation-related genes (LRGs) in osteoporosis (OP) remains unclear. This study aims to clarify the key roles of LRGs and the molecular mechanisms of related biomarkers in OP.
View Article and Find Full Text PDFIndian J Nucl Med
August 2025
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Metastatic renal osteosarcoma is a rare entity. We report a case of a 52-year-old male postright nephrectomy status presented to us with metastatic renal osteosarcoma. 18-fluorine- fluorodeoxyglucose (F-FDG) avid lesions were seen in the right renal bed with extension to adjacent hepatic parenchyma.
View Article and Find Full Text PDF